Hematology Expert Review
Rosai-Dorfman Disease: Sinus Histiocytosis With Massive Lymphadenopathy
Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD
“Don’t be afraid to give up the good to go for the great.” — John D. Rockefeller The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore th...
CAR T-Cell Therapies: Trends and Indications
Syed Ali Abutalib, MD, and Jennifer N. Brudno, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Syed Ali Abutalib, MD and L. Jeffrey Medeiros, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignanc...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Syed Ali Abutalib, MD and L. Jeffrey Medeiros, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignanc...
Cancer Immunology and Immunotherapy: Principles and Practice
Syed Ali Abutalib, MD, and L. Elizabeth Budde, MD, PhD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, we begin a new series of articles on cancer immunology and immunotherapy, in which the authors discuss how immunotherapy has become a major pillar of ca...
Chronic Myelomonocytic Leukemia: Treatment and Prognosis, Part 2
Syed Ali Abutalib, MD, and Mrinal M. Patnaik, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In the concluding half of this two-part installment, which began in our November 25 issue, Drs. Syed Ali Abutalib and Mrinal M. Patnaik continue to explore the current treat...
Chronic Myelomonocytic Leukemia: Treatment and Prognosis, Part 1
Syed Ali Abutalib, MD, and Mrinal M. Patnaik, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and Mrinal M. Patnaik explore the current treatment and prognosis of chronic myelomonocytic leukemia. For each quiz question that...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignanc...
Immunotherapy in B-Cell Non-Hodgkin Lymphomas: Off-the-Shelf Bispecific Antibodies
Syed Ali Abutalib, MD, and Matt Lunning, DO, FACP
Chimeric antigen receptor (CAR) T-cell therapies are a significant advance, but they require careful patient selection, dependency on patients’ own T cells, lymphodepleting chemotherapy, possible bridging therapy, manufacturing timelines with extensive health-care coordination and cost, in addit...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue m...
Allogeneic Transplantation for Hematologic Neoplasms in Adults
Syed Ali Abutalib, MD, and Stephen J. Forman, MD
“The value of experience is not in seeing much, but in seeing wisely.” —Sir William Osler To complement The ASCO Post’s continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting procee...
Conundrums of SARS–CoV-2 Infection in Cancer Care
Syed Ali Abutalib, MD, Nicolaus Kröger, MD, and Malgorzata Mikulska, MD
The ASCO Post is pleased to present the Hematology Expert Review, an occasional feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Kröger, and Mikulska focus on the challenges of providing cancer care amid the COVID-19 pandemic. Here they present two sepa...
CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas
Syed Ali Abutalib, MD, and Miguel-Angel Perales, MD
“The mind is not a vessel to be filled but a fire to be kindled.” —Plutarch About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the re...
High-Risk Multiple Myeloma: Combination Regimens and CAR T-Cell Therapy
Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP
“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s extensive coverage of the 2021 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel treatments under study in high-risk multiple myeloma. For fu...
Newly Diagnosed Multiple Myeloma
Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD
“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on ...
Older Adults With Primary CNS Lymphoma: Treatment Opportunities and Challenges
Syed Ali Abutalib, MD; Shreya Desai, MD; and Lisa M. DeAngelis, MD
The ASCO Post is pleased to present the Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Desai, and DeAngelis explore the treatment of older patients with primary central nervous system lymphoma (PCNSL), which pose importa...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Syed Ali Abutalib, MD, and Stefan O. Ciurea, MD
“Progress lies not in enhancing what is, but in advancing toward what will be.” —Khalil Gibran The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held virtually ...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Syed Ali Abutalib, MD, and Parameswaran Hari, MD
The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...
B-Cell Acute Lymphoblastic Leukemia: Update on Clinical Trials
Syed Ali Abutalib, MD, and Jacob M. Rowe, MD
“Learning never exhausts the mind.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on treatments under stud...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas
Syed Ali Abutalib, MD, and Paolo Strati, MD
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel gene therapies for resistant non-Hodgkin lymphomas (NHL), including ...
Novel Targeted Agents for the Treatment of Myelofibrosis
Syed Ali Abutalib, MD, and Ruben A. Mesa, MD, FACP
“Progress lies not in enhancing what is, but in advancing toward what will be.” –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition...
Selected ASH Abstracts on Novel Treatments of Polycythemia Vera
Syed Ali Abutalib, MD, and Ruben A. Mesa, MD, FACP
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study abstr...
Update on Clinical Trials in Acute Myeloid Leukemia
Syed Ali Abutalib, MD, and Farhad Ravandi, MD
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on acute myeloid leukemia (AML), such as the use of venetoclax added to cladr...
Coagulopathy and COVID-19 Infection
Syed Ali Abutalib, MD, and Jean M. Connors, MD
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” —Hippocrates To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the me...
Novel Insights in Myelodysplastic Syndromes: Highlights From 2020 ASH Meeting
Syed Ali Abutalib, MD, and Peter Greenberg, MD
To complement The ASCO Post’s comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel clinical trial findings in myelodysplastic syndromes (MDS). For full details of th...
Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma
Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD
“There was never a night or a problem that could defeat sunrise or hope.” —Bernard Williams To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceed...
Anti-BCMA–Directed CAR T-Cell Gene Therapy in Relapsed or Refractory Myeloma
Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD
"The noblest pleasure is the joy of understanding.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel...
Novel Approaches in Chronic Lymphocytic Leukemia
Syed Ali Abutalib, MD, and Jennifer R. Brown, MD, PhD
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic approaches in chronic lymphocytic leukemia (CLL). For full d...
Challenges in Managing Hodgkin Lymphoma: Focus on Use of Brentuximab Vedotin
Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO
“I was taught that the way of progress was neither swift nor easy.” —Marie Curie To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two abstracts selected from the meeting proceedings focusing on...
B-Cell and T-Cell Non-Hodgkin Lymphomas
Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin ly...
Novel Therapies Under Study in Chronic Myeloid Leukemia
Syed Ali Abutalib, MD, and Michael J. Mauro, MD
“There is progress whether ye are going forward or backward! The thing is to move.” —Edgar Cayce To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are a few abstracts selected from the meeting proce...
Novel Insights Into Multiple Myeloma
Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD, FASCO
“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for mul...
Allogeneic Hematopoietic Cell Transplantation in Acute Leukemias and Myelodysplastic Syndromes
Syed Ali Abutalib, MD, and Elizabeth J. Shpall, MD
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the use of allogeneic hematopoietic cell transplantation (allo-HCT) in the...
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Neoplasms
Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD
The ASCO Post is pleased to present the Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore extranodal marginal zone lymphoma of mucosa-associated lymphoid neoplasms (MALT lymphomas). For each quiz questio...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue m...
Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies
Syed Ali Abutalib, MD, and Shaji K. Kumar, MD
Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen r...
Red Flag Presentations of Immunoglobulin Light Chain Amyloidosis in Patients With Multiple Myeloma
Syed Ali Abutalib, MD, Lisa Mendelson, APRN-BC, and Vaishali Sanchorawala, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, the authors highlight the most common type of systemic amyloidosis in the United States: immunoglobulin light chain [or amyloid light chain...
Update on Novel Immunotherapies for Plasma Cell Disorders
Syed Ali Abutalib, MD, and Luciano J. Costa, MD, PhD
In this installment of The ASCO Post’s Hematology Expert Review, we take a closer look at the monoclonal antibody targeting CD38, daratumumab, in the treatment of amyloid light chain (AL) amyloidosis and resistant multiple myeloma as well as the antibody-drug conjugate belantamab mafodotin-blmf, w...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Syed Ali Abutalib, MD, Naveen Pemmaraju, MD, and L. Jeffrey Medeiros, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Pemmaraju, and Medeiros highlight the clinically aggressive blastic plasmacytoid dendritic cell neoplasm. For each quiz ques...
Selected ASH Abstracts on Novel Treatments for Non-Hodgkin Lymphomas
Syed Ali Abutalib, MD, AND Sonali M. Smith, MD, FASCO
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for patients with non-Hodgkin lymphomas (NHLs). For full...
Highlights of Research in Lymphomas Presented During the EHA25 Virtual Congress
Syed Ali Abutalib, MD, and Brad Kahl, MD
To complement The ASCO Post’s continued coverage of the virtual edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), here are a few abstracts selected from the meeting proceedings focusing on clinical research in Hodgkin and marginal zone lymphomas. Omission of Rad...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this first-part of a two-part installment, Drs. Abutalib and Medeiros highlight the histologically rare lymphocyte-rich type of classic Hodgkin lymphom...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD
Question 1 Which of the following statements about mixed-cellularity classic Hodgkin lymphoma is correct? A. It has a female predominance. B. This type of classic Hodgkin lymphoma is relatively more common in developing nations and is frequently associated with Epstein-Barr virus (EBV) positivity...
Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia
Syed Ali Abutalib, MD and Saad Z. Usmani, MD, FACP
GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-...
Hypercoagulability in Critically Ill Patients With COVID-19: Where Do We Stand?
Syed Ali Abutalib, MD, and Jean M. Connors, MD
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” ―Hippocrates The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Connors consi...
Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Syed Ali Abutalib, MD, and John M. Pagel, MD, PhD
ABSTRACT 355: MURANO study: Four-year analysis confirms sustained benefit (compared to bendamustine and rituximab; n = 195) of time-limited venetoclax/rituximab (n = 194) in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; ClinicalTrials.gov NCT02005471)1 Met...
Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Syed Ali Abutalib, MD, and John M. Pagel, MD, PhD
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed chronic lymphocytic leukemia (CLL) and sma...
Selected ASH Abstracts on Novel Treatments in Acute Lymphoblastic Leukemia
Syed Ali Abutalib, MD, and Daniel J. DeAngelo, MD, PhD
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed and relapsed or refractory acute lymphobla...
Updates in Hematopoietic Cell Transplantation
Syed Ali Abutalib, MD, and Navneet Majhail, MD, MS
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic and autologous hematopoietic cell transplantation. For full details...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas: Present and Future
SYED ALI ABUTALIB, MD, AND SATTVA S. NEELAPU, MD
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel immunotherapies for patients with different types of non-Hodgkin lymphom...
